Concord Drugs Ltd Share Price

38.84
(0.47%)
Jul 23, 2024|03:48:00 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open38.66
  • Day's High39.44
  • 52 Wk High61.5
  • Prev. Close38.66
  • Day's Low37
  • 52 Wk Low26
  • Turnover (lac)1.79
  • P/E92.05
  • Face Value10
  • Book Value33.82
  • EPS0.42
  • Mkt. Cap (Cr.)38.84
  • Div. Yield0
No Records Found

Concord Drugs Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

38.66

Prev. Close

38.66

Turnover(Lac.)

1.79

Day's High

39.44

Day's Low

37

52 Week's High

61.5

52 Week's Low

26

Book Value

33.82

Face Value

10

Mkt Cap (₹ Cr.)

38.84

P/E

92.05

EPS

0.42

Divi. Yield

0

Concord Drugs Ltd Corporate Action

15 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

12 Sep 2023

12:00 AM

BookCloser

arrow

12 Sep 2023

12:00 AM

AGM

Announcement Date: 12 Sep, 2023

arrow

Concord Drugs Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Concord Drugs Ltd SHAREHOLDING SNAPSHOT

23 Jul, 2024|02:10 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 55.40%

Foreign: 0.00%

Indian: 55.40%

Non-Promoter- 44.59%

Institutions: 0.00%

Non-Institutions: 44.59%

Custodian: 0.00%

Share Price

Concord Drugs Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

9.88

8.74

8.74

8.74

Preference Capital

0

0

0

0

Reserves

21.83

19.62

18.02

14.74

Net Worth

31.71

28.36

26.76

23.48

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

51.35

51.33

51.79

57.48

yoy growth (%)

0.03

-0.88

-9.9

13.43

Raw materials

-42.17

-42.57

-43.29

-46.1

As % of sales

82.12

82.93

83.59

80.19

Employee costs

-3.75

-3.5

-1.97

-2.8

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

0.52

0.45

0.63

0.64

Depreciation

-1.36

-1.46

-2.4

-2.58

Tax paid

-1.01

-0.12

-0.31

-0.48

Working capital

5.74

1.76

11.4

-13.41

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

0.03

-0.88

-9.9

13.43

Op profit growth

-3.71

-30.16

-13.02

-33.22

EBIT growth

-2.55

-20.71

-16.11

-45.68

Net profit growth

899.6

1.23

103.25

-90.87

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022

Gross Sales

44.92

52.08

58.96

Excise Duty

0

0

0

Net Sales

44.92

52.08

58.96

Other Operating Income

0.01

0.01

0.1

Other Income

0

0

0

Concord Drugs Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,587.9

124.833,80,990.4867.60.855,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,534.75

76.421,20,383.365310.662,259507.93

Cipla Ltd

CIPLA

1,489.7

32.381,20,295.961,038.40.573,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,154.4

33.791,16,159.651,405.20.263,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,769.25

26.361,12,931.21,034.80.595,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Concord Drugs Ltd

Management

Register Office

Registrar Office

Chairman & Managing Director

S Nagi Reddy

Independent Director

K Ramchandra Reddy

Whole Time Director & CFO

Koni Reddy

Independent Director

S. Nagavenkata Hareesh

Whole-time Director

S. Manoj Kumar Reddy

Independent Director

Summela Kasu

Company Sec. & Compli. Officer

Namratha Nagla

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved. The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad. State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality.The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing. It is engaged in developing New products Viz MUPS (Multiple Unit Pellet System), Sustained Release, Modified Release pellets with Innovative Drug Delivery Technologies by utilizing best and latest processing machinery. It operates a state of the art, cGMP contract manufacturing Formulation-Fill-Finish facility, providing comprehensive pharmaceutical development and manufacturing services for drug products.
Read More

Company FAQs

What is the Concord Drugs Ltd share price today?

Down Arrow

The Concord Drugs Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹38.84 today.

What is the Market Cap of Concord Drugs Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Concord Drugs Ltd is ₹38.84 Cr. as of 23 Jul ‘24

What is the PE and PB ratio of Concord Drugs Ltd?

Down Arrow

The PE and PB ratios of Concord Drugs Ltd is 92.05 and 1.14 as of 23 Jul ‘24

What is the 52 Week High and Low of Concord Drugs Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Concord Drugs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Concord Drugs Ltd is ₹26 and ₹61.5 as of 23 Jul ‘24

What is the CAGR of Concord Drugs Ltd?

Down Arrow

Concord Drugs Ltd's CAGR for 5 Years at 12.56%, 3 Years at 10.44%, 1 Year at 46.44%, 6 Month at -6.41%, 3 Month at 4.66% and 1 Month at -0.57%.

What is the shareholding pattern of Concord Drugs Ltd?

Down Arrow

The shareholding pattern of Concord Drugs Ltd is as follows:
Promoters - 55.41 %
Institutions - 0.00 %
Public - 44.59 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.